EMA starts safety-related review of obesity drug
The EMA has started a review of drugs containing substance amfepramone, which is typically used to dampen appetites as a treatment for obesity.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Following a request from the Romanian medicines agency, the European Medicines Agency (EMA) has started reviewing the substance amfepramone, which is an ingredient in several drugs used for treating obesity.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
EMA clarifies: No Russian application for vaccine approval
For subscribers
